- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05873543
Effekten av ett smarttelefonassisterat hybridhjärtrehabiliteringsprogram hos patienter med hjärtsvikt. (SHCR-HF)
The aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with HF. Participants will undergo a 12-week program led by a case manager and assisted by a smartphone. The study aims to answer two main questions:
- Is the novel cardiac rehabilitation model feasible for patients with HF?
- Does the intervention group show a significant improvement in exercise capacity and adherence compared to the usual care group?
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Hung-Jui Chuang, MD
- Telefonnummer: 67034 00886-2-23123456
- E-post: rexintwo@gmail.com
Studieorter
-
-
-
Taipei, Taiwan
- Rekrytering
- Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
-
Kontakt:
- Hung-Jui Chuang, MD
- Telefonnummer: 67034 00886-2-23123456
- E-post: rexintwo@gmail.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients with heart failure between the ages of 18 and 80 years old.
- NYHA (New York Heart Association) functional classification of 1 to 3.
- Patients must be in a stable condition and under outpatient follow-up.
Exclusion Criteria:
- Patients who have contraindications for exercise according to the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription.
- Patients who are unable to complete cardiopulmonary exercise testing.
- Patients who are unable to follow verbal instructions.
- Patients who are unable to walk independently or pedal a stationary bicycle.
- Patients who are unable to use communication app on a smartphone.
- Patients who already engage in physical activity exceeding the recommended moderate intensity of 150 minutes per week or are currently participating in cardiac rehabilitation.
- Patients who do not provide consent to participate in the trial.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: smartphone-assisted hybrid cardiac rehabilitation (SHCR)
Participants receive a 12-wk case manager-led smartphone-assisted hybrid cardiac rehabilitation with follow-up at 12 week and 6 months. |
The 12-week case manager-led SHCR program includes:
|
|
Inget ingripande: Usual care
Participants receive usual care including general education and exercise suggestion. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change of peak oxygen uptake
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
Peak oxygen uptake will be assessed using cardiopulmonary exercise test before intervention, at 12 weeks (post-intervention), and at 6 months. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Change of 6 minute walking test
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
6 minute walking test will be performed before intervention, at 12 weeks (post-intervention), and at 6 months. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Adherence to prescribed exercise
Tidsram: 12 weeks(post-intervention)
|
We will evaluate the percentage of completed prescribed exercises at 12 weeks. |
12 weeks(post-intervention)
|
|
Evaluation of Quality of life
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in 36-Item Short Form Survey(SF-36). |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Depression
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in Patient Health Questionnaire (PHQ-9). The PHQ-9 score ranges from 0-27. Higher scores indicate worsen symptoms. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Anxiety
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in Generalized Anxiety Disorder scale (GAD-7). The GAD-7 score ranges 0-21. Higher scores indicate worsen symptoms. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of physical activity
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in physical activity using International Physical Activity Questionnaire(IPAQ) Taiwan version. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of grip strength
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The grip strength will be measured using a grip goniometer with the participants seated and the elbow flexed at 90 degrees. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of frailty
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will evaluate the change in the Clinical Frailty Scale, which ranges from 1 to 9. Higher scores represent greater illness. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: Total cholesterol
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The Total cholesterol will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: LDL
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The LDL will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: HDL
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The HDL will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: Triglyceride
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The Triglyceride will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: NT-proBNP
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.
|
The NT-proBNP will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Hung-Jui Chuang, MD, Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 202302009RINC
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .